Fractionated stereotactic radiotherapy boost after post-operative radiotherapy in patients with high-grade gliomas
Introduction
High-grade gliomas are the most common of all CNS tumours. Primary treatment options include surgical resection and radiotherapy. The effectiveness of radiotherapy in terms of a survival benefit was demonstrated in prospective randomized studies [1], [38], [39], [40]. There is evidence of a dose response relationship with doses of ≤60 Gy [1]. However, the Radiation Therapy Oncology Group (RTOG)/Eastern Cooperative Oncology Group (ECOG) study with an additional boost of 10 Gy to a total dose of 70 Gy in a large volume did not result in further improvement of survival [4]. The main pattern of failure is local and local control of high-grade glioma may be achieved by increasing the dose to the tumour without increasing the dose to normal brain tissue. Therefore, stereotactic radiotherapy (SRT) was proposed for dose escalation with doses of >70 Gy.
Focal radiotherapy has been used in the treatment of recurrent gliomas or as a boost in the initial management with encouraging preliminary results. It was administered by interstitial brachytherapy (IRT) [11], [12], [20], [21], as SRT [19], [30], as radiosurgery [14], [32], [36] or as an integrated boost with intensity-modulated radiotherapy [35]. Single-dose irradiation or radiosurgery carries an increased risk of radiation necrosis [31]. Published data suggest that fractionated SRT is associated with a lower incidence of necrosis compared with IRT [19], [26], [30]. Fractionated SRT combines the radiobiological advantages (normal tissue sparing) and precise focal dose delivery [9], [10], [15].
This prospective study was conducted in order to assess the value of a fractionated stereotactic boost after conventional radiotherapy with respect to survival, local control and toxicity in the initial management of selected patients with malignant glioma.
Section snippets
Inclusion criteria
For this study the same design as for the randomized phase III EORTC 22972 trial was used. Eligible patients were those with malignant high-grade glioma (WHO grade III/IV), enhancing tumours of ≤4 cm in maximum diameter on pre-operative imaging (computed tomography (CT) or magnetic resonance imaging (MRI)), age between 18 and 65 years and WHO performance status of 0–2 (Table 1).
Patient characteristics
Between March 1997 and June 1999, 17 patients (11 male, six female) met the inclusion criteria (see Section 2.1 and
Overall survival
The median follow-up was 25 months (range 9–50 months). Twelve patients died and five patients were still alive at the time of the analysis. The median overall survival for all patients is 20 months, with a survival of 77%, 42%, 28%, and 22% at 1, 2, 3, and 4 years, respectively (Fig. 1). The overall and progression-free survival for the 15 patients with the diagnosis of a glioblastoma multiforme (WHO grade IV) were not significantly different: the median survival was 19 months. Survival
Discussion
Compared with historical reports, the combination of single fraction radiosurgery (SRS) and conventional external beam radiotherapy in the initial management of patients with malignant gliomas has not conclusively proved to result in an increase in survival. The increase in survival which has been shown in studies using an interstitial radiotherapy boost is supposed to be mainly the result of patient selection [7]. In phase II studies with an additional IRT boost [12], [21], [41] the reported
References (41)
- et al.
Linac radiosurgery for high-grade gliomas: the University of Florida experience
Int J Radiat Oncol Biol Phys
(1995) - et al.
Stereotactic radiosurgery as an adjunct to surgery and external beam radiotherapy in the treatment of patients with malignant gliomas
Int J Radiat Oncol Biol Phys
(1995) - et al.
A non-invasive, relocatable stereotactic frame for fractionated radiotherapy and multiple imaging
Radiother Oncol
(1991) - et al.
External irradiation followed by an interstitial high activity iodine-125 implant “boost” in the initial treatment of malignant gliomas: NCOG study 6G-82-2
Int J Radiat Oncol Biol Phys
(1991) Moving targets and ghosts of the past: outcome measurement in brain tumour therapy
J Clin Neurosci
(2002)- et al.
A non-invasive method for fractionated stereotactic irradiation of brain tumours with linear accelerator
Radiother Oncol
(1990) - et al.
A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma
Int J Radiat Oncol Biol Phys
(1999) - et al.
Efficacy and toxicity of fractionated stereotactic radiotherapy in the treatment of recurrent gliomas (phase I/II study)
Radiother Oncol
(1993) - et al.
Survival and quality of life after interstitial implantation of removable high-activity Iodine-125 sources for the treatment of patients with recurrent malignant gliomas
Int J Radiat Oncol Biol Phys
(1989) - et al.
Accelerated hyperfractionated radiotherapy in 149 patients with glioblastoma multiforme
Radiother Oncol
(1999)
A population-based study of glioblastoma multiforme
Int J Radiat Oncol Biol Phys
Radiosurgery in the initial management of malignant gliomas: survival comparison with the RTOG recursive partitioning analysis
Int J Radiat Oncol Biol Phys
Stereotactically guided fractionated radiotherapy: technical aspects
Radiother Oncol
Hypofractionated stereotactic radiotherapy in the management of recurrent glioma
Int J Radiat Oncol Biol Phys
Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results in three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials
Int J Radiat Oncol Biol Phys
Use of the RTOG recursive partitioning analysis to validate the benefit of iodine-125 implants in the primary treatment of malignant gliomas
Int J Radiat Oncol Biol Phys
An analysis of dose-effect relationship in the radiotherapy of malignant gliomas
Int J Radiat Oncol Biol Phys
A Medical Cancer Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party
Br J Cancer
Accelerated radiotherapy regimen for malignant gliomas using stereotactic concomitant boosts for dose escalation
Radiat Oncol Invest
Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas
Cancer
Cited by (48)
Radiotherapy in adult glioblastomas
2010, NeurochirurgieSystematic review of stereotactic radiotherapy for high-grade gliomas
2010, Cancer/RadiotherapieCurrent practices and future directions of therapeutic strategy in glioblastoma: Survival benefit and indication of BNCT
2009, Applied Radiation and IsotopesBoron neutron capture therapy for newly diagnosed glioblastoma
2009, Radiotherapy and OncologyEORTC 22972-26991/MRC BR10 trial: Fractionated stereotactic boost following conventional radiotherapy of high grade gliomas. Clinical and quality-assurance results of the stereotactic boost arm
2008, Radiotherapy and OncologyCitation Excerpt :In our experience, an additional boost of 20 Gy in 4 fractions following conventionally fractionated irradiation with 60 Gy was a reasonably safe treatment option. The results are similar to the preceding single centre experience of one radiation necrosis in 17 patients [34] and lower than the reported following single fraction radiosurgery boost. In a randomized study (RTOG 93-05), 7 out of 28 patients receiving radiosurgery boost (15–24 Gy) had to undergo a re-operation compared to 3 out of 31 patients not receiving additional treatment [35].